Interleukin‐2‐induced skin inflammation
Open Access
- 2 March 2024
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 54 (4) , e2350580
Abstract
Recombinant human IL‐2 has been used to treat inflammatory diseases and cancer; however, side effects like skin rashes limit the use of this therapeutic. To identify key molecules and cells inducing this side effect, we characterized IL‐2‐induced cutaneous immune reactions and investigated the relevance of CD25 (IL‐2 receptor α) in the process. We injected IL‐2 intradermally into WT mice and observed increases in immune cell subsets in the skin with preferential increases in frequencies of IL‐4‐ and IL‐13‐producing group 2 innate lymphoid cells and IL‐17‐producing dermal γδ T cells. This overall led to a shift toward type 2/type 17 immune responses. In addition, using a novel topical genetic deletion approach, we reduced CD25 on skin, specifically on all cutaneous cells, and found that IL‐2‐dependent effects were reduced, hinting that CD25 — at least partly — induces this skin inflammation. Reduction of CD25 specifically on skin Tregs further augmented IL‐2‐induced immune cell infiltration, hinting that CD25 on skin Tregs is crucial to restrain IL‐2‐induced inflammation. Overall, our data support that innate lymphoid immune cells are key cells inducing side effects during IL‐2 therapy and underline the significance of CD25 in this process.Keywords
This publication has 48 references indexed in Scilit:
- Interleukin-2 maintains the survival of interleukin-17+ gamma/delta T cells in inflammation and autoimmune diseasesInternational Immunopharmacology, 2020
- IL-33-Dependent Group 2 Innate Lymphoid Cells Promote Cutaneous Wound HealingJournal of Investigative Dermatology, 2016
- Activation status of γδ T cells dictates their effect on osteoclast generation and bone resorptionBone Reports, 2015
- Composition of Innate Lymphoid Cell Subsets in the Human Skin: Enrichment of NCR+ ILC3 in Lesional Skin and Blood of Psoriasis PatientsJournal of Investigative Dermatology, 2014
- The Ubiquitin Ligase Stub1 Negatively Modulates Regulatory T Cell Suppressive Activity by Promoting Degradation of the Transcription Factor Foxp3Immunity, 2013
- IL-33 induces innate lymphoid cell–mediated airway inflammation by activating mammalian target of rapamycinJournal of Allergy and Clinical Immunology, 2012
- Utilization of the beta and gamma chains of the IL‐2 receptor by the novel cytokine IL‐15.The EMBO Journal, 1994
- Cutaneous side effects associated with interleukin 2 administration for metastatic melanomaJournal of the American Academy of Dermatology, 1993
- Immunopathological changes in the skin following recombinant interleukin‐2 treatmentThe Journal of Pathology, 1992
- Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cellsEuropean Journal of Immunology, 1992